Quick Answer
Pasithea Therapeutics Corp. reported Cash and Equivalents of $55.16 million for fiscal year 2025.
Pasithea Therapeutics Corp. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $55.16M | +696.8% |
| 2024 | $6.92M | -57.6% |
| 2023 | $16.33M | -50.6% |
| 2022 | $33.09M | -37.5% |
| 2021 | $52.97M | +21638.8% |
| 2020 | $243.7K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.12M | -56.0% | -42.9% |
| June 30, 2025 | $7.22M | -9.4% | +35.1% |
| March 31, 2025 | $5.34M | -55.5% | -22.8% |
| December 31, 2024 | $6.92M | -57.6% | -26.0% |
| September 30, 2024 | $9.36M | -52.2% | +17.5% |
| June 30, 2024 | $7.97M | -70.1% | -33.7% |
| March 31, 2024 | $12.01M | -59.9% | -26.5% |
| December 31, 2023 | $16.33M | -50.6% | -16.6% |
- Pasithea Therapeutics Corp. showed an increase of +696.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Pasithea Therapeutics Corp.’s cash and equivalents has grown by 22538.6% (from $243.7 thousand to $55.16 million).
- The most recent figure is from Pasithea Therapeutics Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: